Ubs Asset Management Americas Inc Acadia Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 342,882 shares of ACAD stock, worth $7.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

342,882

Previous 251,056 36.58%

Holding current value

$7.39 Million

Previous $4.17 Million 77.34%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$14.1 - $22.95 $1.29 Million - $2.11 Million	91,826 Added 36.58%	342,882 $7.4 Million
Q1 2025 May 19, 2025	BUY	$16.61 - $20.29 $530,373 - $647,879	31,931 Added 14.57%	251,056 $4.17 Million
Q4 2024 Feb 14, 2025	BUY	$14.29 - $18.76 $419,925 - $551,281	29,386 Added 15.49%	219,125 $4.02 Million
Q3 2024 Nov 14, 2024	SELL	$15.14 - $19.14 $421,739 - $533,163	-27,856 Reduced 12.8%	189,739 $2.92 Million
Q2 2024 Aug 13, 2024	BUY	$14.62 - $18.42 $1.44 Million - $1.81 Million	98,252 Added 82.33%	217,595 $3.54 Million
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $53,458 - $92,734	-3,005 Reduced 2.46%	119,343 $2.21 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $74,911 - $114,530	3,605 Added 3.04%	122,348 $3.83 Million
Q3 2023 Nov 13, 2023	SELL	$20.84 - $33.47 $164,052 - $263,475	-7,872 Reduced 6.22%	118,743 $2.47 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $2.07 Million - $2.65 Million	126,615 New	126,615 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $6.93 Million - $8.98 Million	-491,336 Reduced 79.95%	123,201 $0
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $548,917 - $1.15 Million	42,192 Added 7.37%	614,537 $0
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $635,570 - $834,680	30,352 Added 5.6%	572,345 $0
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $1.31 Million - $2.12 Million	78,185 Added 16.86%	541,993 $0
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $333,415 - $523,365	-21,129 Reduced 4.36%	463,808 $0
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $1.58 Million - $2.23 Million	81,312 Added 20.15%	484,937 $0
Q1 2021 May 14, 2021	SELL	$25.02 - $54.99 $4.28 Million - $9.42 Million	-171,220 Reduced 29.79%	403,625 $0
Q4 2020 Mar 01, 2021	SELL	$41.04 - $56.79 $610,716 - $845,091	-14,881 Reduced 2.52%	574,845 $0
Q3 2020 Nov 13, 2020	SELL	$36.42 - $57.0 $12 Million - $18.8 Million	-329,928 Reduced 35.88%	589,726 $0
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $5.66 Million - $7.6 Million	144,052 Added 18.57%	919,654 $0
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $2.7 Million - $3.99 Million	-85,195 Reduced 9.9%	775,602 $0
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $27.1 Million - $38.5 Million	749,288 Added 671.95%	860,797 $0
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $154,251 - $305,517	6,942 Added 6.64%	111,509 $0
Q2 2019 Aug 15, 2019	BUY	$23.32 - $28.12 $239,566 - $288,876	10,273 Added 10.89%	104,567 $0
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $211,810 - $358,650	13,099 Added 16.13%	94,294 $0
Q4 2018 Feb 13, 2019	BUY	$14.32 - $22.92 $181,105 - $289,869	12,647 Added 18.45%	81,195 $0
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $247 - $414	19 Added 0.03%	68,548 $0
Q2 2018 Aug 14, 2018	SELL	$15.07 - $22.34 $8.18 Million - $12.1 Million	-543,117 Reduced 88.8%	68,529 $0
Q1 2018 May 14, 2018	SELL	$22.47 - $32.33 $6.24 Million - $8.98 Million	-277,730 Reduced 31.23%	611,646 $0
Q4 2017 Feb 09, 2018	BUY	$26.84 - $39.14 $2.78 Million - $4.05 Million	103,583 Added 13.18%	889,376 $0
Q3 2017 Nov 13, 2017	BUY	$29.49 - $38.37 $23.2 Million - $30.2 Million	785,793	785,793 $0

Others Institutions Holding ACAD

# of Institutions

345

Shares Held

163M

Call Options Held

811K

Put Options Held

334K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.49B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Acadia Pharmaceuticals Inc Transaction History